Found: 6
Select item for more details and to access through your institution.
Targeting CD137 enhances the efficacy of cetuximab.
- Published in:
- Journal of Clinical Investigation, 2014, v. 124, n. 6, p. 2668, doi. 10.1172/JCI73014
- By:
- Publication type:
- Article
FAT/CD36 Participation in Human Skeletal Muscle Lipid Metabolism: A Systematic Review.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 1, p. 318, doi. 10.3390/jcm12010318
- By:
- Publication type:
- Article
Targeting CD137 enhances the efficacy of cetuximab.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
- Published in:
- PLoS ONE, 2023, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0276651
- By:
- Publication type:
- Article
Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
- Published in:
- Head & Neck, 2015, v. 37, n. 8, p. 1102, doi. 10.1002/hed.23714
- By:
- Publication type:
- Article
Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
- Published in:
- Oncologist, 2018, v. 23, n. 7, p. 764, doi. 10.1634/theoncologist.2017-0618
- By:
- Publication type:
- Article